FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid ...
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025
We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...
Axsome gets FDA approval for Symbravo for migraine
Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...
10 Best ASX Stocks to Buy According to Hedge Funds
According to a report by the Australian Bureau of Statistics (ABS) published on December 4, 2024, the Australian economy grew ...
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...
Hosted on MSN6h
Is Tonix Pharmaceuticals the Next Biotech Breakout?
Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...
10 Unstoppable Stocks to Buy in 2025
As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a ...
manilatimes4h
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company”), a pharmaceutical company focused on developing new ...
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...
Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025?
We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where ...
Chimerix stock soars to 52-week high, hits $4.22
Chimerix Inc (NASDAQ: NASDAQ:CMRX) stock has reached a new 52-week high, touching $4.22 in recent trading, giving the company a market capitalization of $375 million. According to InvestingPro data, ...
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...